154 related articles for article (PubMed ID: 9881891)
1. Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy.
Sato K; Shiraki M
Endocr J; 1998 Aug; 45(4):431-9. PubMed ID: 9881891
[TBL] [Abstract][Full Text] [Related]
2. Saccharated ferric oxide (SFO)-induced osteomalacia: in vitro inhibition by SFO of bone formation and 1,25-dihydroxy-vitamin D production in renal tubules.
Sato K; Nohtomi K; Demura H; Takeuchi A; Kobayashi T; Kazama J; Ozawa H
Bone; 1997 Jul; 21(1):57-64. PubMed ID: 9213008
[TBL] [Abstract][Full Text] [Related]
3. [Drug-induced osteomalacia].
Sato K
Clin Calcium; 2007 Oct; 17(10):1536-42. PubMed ID: 17906405
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide.
Yamamoto S; Okada Y; Mori H; Fukumoto S; Tanaka Y
Intern Med; 2012; 51(17):2375-8. PubMed ID: 22975552
[TBL] [Abstract][Full Text] [Related]
5. Iatrogenic osteomalacia: report of two cases.
Yamamoto S; Okada Y; Mori H; Kurozumi A; Torimoto K; Arao T; Tanaka Y
J UOEH; 2013 Mar; 35(1):25-31. PubMed ID: 23475021
[TBL] [Abstract][Full Text] [Related]
6. Iatrogenic osteomalacia caused by intravenous administration of saccharated ferric oxide.
Suzuki A; Ohoike H; Matsuoka Y; Irimajiri S
Am J Hematol; 1993 May; 43(1):75-6. PubMed ID: 8317471
[No Abstract] [Full Text] [Related]
7. Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports.
Vilaca T; Velmurugan N; Smith C; Abrahamsen B; Eastell R
J Bone Miner Res; 2022 Jun; 37(6):1188-1199. PubMed ID: 35426179
[TBL] [Abstract][Full Text] [Related]
8. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.
Shimizu Y; Tada Y; Yamauchi M; Okamoto T; Suzuki H; Ito N; Fukumoto S; Sugimoto T; Fujita T
Bone; 2009 Oct; 45(4):814-6. PubMed ID: 19555782
[TBL] [Abstract][Full Text] [Related]
9. [Case report; A case of FGF23-related hypophosphatemic osteomalacia caused by long-term administration of saccharated ferric oxide].
Wada Y; Kinoshita Y; Taguchi M; Fukumoto S; Fujita T
Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):3031-3. PubMed ID: 22175146
[No Abstract] [Full Text] [Related]
10. [A case of hypophosphatemia induced by intravenous administration of saccharated iron oxide].
Konjiki O; Fukaya S; Kanou H; Imamura T; Iwamoto T; Takasaki M
Nihon Ronen Igakkai Zasshi; 1994 Oct; 31(10):805-10. PubMed ID: 7853746
[TBL] [Abstract][Full Text] [Related]
11. [Bone and Nutrition. The relationship between iron and phosphate metabolism].
Takashi Y; Fukumoto S
Clin Calcium; 2015 Jul; 25(7):1037-42. PubMed ID: 26119317
[TBL] [Abstract][Full Text] [Related]
12. Hypophosphatemia induced by intravenous administration of Saccharated iron oxide.
Okada M; Imamura K; Iida M; Fuchigami T; Omae T
Klin Wochenschr; 1983 Jan; 61(2):99-102. PubMed ID: 6843038
[TBL] [Abstract][Full Text] [Related]
13. A case of osteomalacia due to deranged mineral balance caused by saccharated ferric oxide and short-bowel syndrome: A case report.
Nomoto H; Miyoshi H; Nakamura A; Nagai S; Kitao N; Shimizu C; Atsumi T
Medicine (Baltimore); 2017 Sep; 96(39):e8147. PubMed ID: 28953654
[TBL] [Abstract][Full Text] [Related]
14. Uncommon adverse effect of a common medication.
Moore KL; Kildahl-Andersen O; Kildahl-Andersen R; Tjønnfjord GE
Tidsskr Nor Laegeforen; 2013 Jan; 133(2):165. PubMed ID: 23344600
[No Abstract] [Full Text] [Related]
15. Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study.
Kawabata H; Tamura T; Tamai S; Fujibayashi A; Sugimura M;
Int J Hematol; 2022 Nov; 116(5):647-658. PubMed ID: 35790696
[TBL] [Abstract][Full Text] [Related]
16. A Case of an Insufficiency Fracture of the Medial Proximal Tibia Secondary to Osteomalacia Associated with Long-Term Saccharated Ferric Oxide Administration.
Ishimaru D; Sumi H
Case Rep Orthop; 2017; 2017():1675654. PubMed ID: 28744387
[TBL] [Abstract][Full Text] [Related]
17. Hypophosphatemic osteomalacia induced by intravenous iron therapy: a case report.
Samões B; Silva B; Martins A; Oliveira D; Rajão Martins F; Fonseca D; Costa L; Bernardes M
Joint Bone Spine; 2023 Sep; 90(5):105586. PubMed ID: 37127260
[TBL] [Abstract][Full Text] [Related]
18. Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study.
Ikuta K; Hanashi H; Hirai K; Ota Y; Matsuyama Y; Shimura A; Terauchi M; Momoeda M
Int J Hematol; 2019 Jan; 109(1):41-49. PubMed ID: 30039442
[TBL] [Abstract][Full Text] [Related]
19. [Updates on rickets and osteomalacia: FGF23-mediated hypophosphatemic rickets/osteomalacia].
Michigami T
Clin Calcium; 2013 Oct; 23(10):1429-35. PubMed ID: 24076640
[TBL] [Abstract][Full Text] [Related]
20. Effect of saccharated ferric oxide and iron dextran on the metabolism of phosphorus in rats.
Sanai T; Oochi N; Okada M; Imamura K; Okuda S; Iida M
J Lab Clin Med; 2005 Jul; 146(1):25-9. PubMed ID: 16025088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
